PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
57.13
ESG score 90-95% of Biotechnology median of 60.98. John Neff would demand higher returns to compensate for below-average ESG risk management.
53.68
Environmental score 90-95% of Biotechnology median of 56.87. John Neff would demand higher returns to compensate for below-average climate risk management.
57.71
Social score 80-90% of Biotechnology median of 64.30. Martin Whitman would look for hidden social liabilities and reputational risks.
60.00
Governance score near Biotechnology median of 62.55. David Dodd would investigate if industry-standard governance adequately protects shareholder interests.